Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728691 | 0.77 | EGLN1 (0.40) | SLC22A6EGLN1TGFBR1TDP1TSHR | |
| Malic Acid SCHEMBL16245057 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2SLC22A6EGLN1MAPTTGFBR1 | |
| SCHEMBL206973 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6MAPTGABRR1LMNA | |
| SCHEMBL9040323 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6MAPTGABRR1LMNA | |
| SCHEMBL28474210 | 0.76 | TSHR (0.38) | EGLN1TGFBR1TSHRALDH1A1 | |
| SCHEMBL222024 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6MAPTGABRR1LMNA | |
| SCHEMBL4888817 | 0.76 | TSHR (0.38) | EGLN1TGFBR1TSHRALDH1A1 | |
| SCHEMBL17398486 | 0.76 | EGLN1 (0.39) | SMN1; SMN2SLC22A6EGLN1MAPTTGFBR1 | |
| SCHEMBL8218807 | 0.76 | EGLN1 (0.39) | SLC22A6EGLN1TGFBR1GABRR1LMNA | |
| Ammonia Solution, Strong SCHEMBL21219123 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2SLC22A6MAPTGABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9719079-B2 | Aldolases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-08-01 | — | — | US | disclosed |
| EP-3153580-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF Enzymes LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9518280-B2 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL, INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2385108-B1 | Aldolases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160251643-A1 | Aldolases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION | 2016-09-01 | — | — | US | disclosed |
| US-9290755-B2 | Aldolases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150111260-A1 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED | 2015-04-23 | — | — | US | disclosed |
| US-9005938-B2 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL, INCORPORATED (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2322643-B1 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2316962-B1 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20100095390-A1 | Aldolases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION | 2010-04-15 | — | — | US | disclosed |
| EP-2112227-A1 | Aldolases, nucleic acids encoding them and methods for making and using them | Cargill, Incorporated (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1999256-A4 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1999256-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | Verenium Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1994161-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080020435-A1 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL, INCORPORATED (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007103989-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103389-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL INC (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007103389-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103989-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100095390-A1 | Aldolases, Nucleic Acids Encoding Them and Methods for Making and Using Them | DERA, ALDOA, TKT | SMN1; SMN2 1658/4885SLC22A6 1965/4885EGLN1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.